Autosomal dominant and sporadic late onset Alzheimer's disease share a common in vivo pathophysiology.
Alzheimer pathophysiology
biomarkers
rates of change
Journal
Brain : a journal of neurology
ISSN: 1460-2156
Titre abrégé: Brain
Pays: England
ID NLM: 0372537
Informations de publication
Date de publication:
21 10 2022
21 10 2022
Historique:
received:
29
11
2021
revised:
12
04
2022
accepted:
27
04
2022
pubmed:
18
5
2022
medline:
26
10
2022
entrez:
17
5
2022
Statut:
ppublish
Résumé
The extent to which the pathophysiology of autosomal dominant Alzheimer's disease corresponds to the pathophysiology of 'sporadic' late onset Alzheimer's disease is unknown, thus limiting the extrapolation of study findings and clinical trial results in autosomal dominant Alzheimer's disease to late onset Alzheimer's disease. We compared brain MRI and amyloid PET data, as well as CSF concentrations of amyloid-β42, amyloid-β40, tau and tau phosphorylated at position 181, in 292 carriers of pathogenic variants for Alzheimer's disease from the Dominantly Inherited Alzheimer Network, with corresponding data from 559 participants from the Alzheimer's Disease Neuroimaging Initiative. Imaging data and CSF samples were reprocessed as appropriate to guarantee uniform pipelines and assays. Data analyses yielded rates of change before and after symptomatic onset of Alzheimer's disease, allowing the alignment of the ∼30-year age difference between the cohorts on a clinically meaningful anchor point, namely the participant age at symptomatic onset. Biomarker profiles were similar for both autosomal dominant Alzheimer's disease and late onset Alzheimer's disease. Both groups demonstrated accelerated rates of decline in cognitive performance and in regional brain volume loss after symptomatic onset. Although amyloid burden accumulation as determined by PET was greater after symptomatic onset in autosomal dominant Alzheimer's disease than in late onset Alzheimer's disease participants, CSF assays of amyloid-β42, amyloid-β40, tau and p-tau181 were largely overlapping in both groups. Rates of change in cognitive performance and hippocampal volume loss after symptomatic onset were more aggressive for autosomal dominant Alzheimer's disease participants. These findings suggest a similar pathophysiology of autosomal dominant Alzheimer's disease and late onset Alzheimer's disease, supporting a shared pathobiological construct.
Identifiants
pubmed: 35580594
pii: 6587090
doi: 10.1093/brain/awac181
pmc: PMC9989348
doi:
Substances chimiques
Amyloid beta-Peptides
0
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
3594-3607Subventions
Organisme : NIA NIH HHS
ID : U01 AG024904
Pays : United States
Organisme : NIA NIH HHS
ID : K01 AG053474
Pays : United States
Organisme : NIA NIH HHS
ID : P01 AG003991
Pays : United States
Organisme : NIA NIH HHS
ID : P01 AG026276
Pays : United States
Organisme : NIA NIH HHS
ID : U19 AG024904
Pays : United States
Organisme : NIA NIH HHS
ID : UF1 AG032438
Pays : United States
Organisme : NIH HHS
ID : S10 OD025214
Pays : United States
Organisme : NIA NIH HHS
ID : U19 AG032438
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG072979
Pays : United States
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
Brain. 1999 Sep;122 ( Pt 9):1709-19
pubmed: 10468510
Sci Transl Med. 2014 Mar 19;6(228):228fs13
pubmed: 24648338
Brain. 2008 Mar;131(Pt 3):665-80
pubmed: 18263627
Neuroimage. 2015 Feb 15;107:55-64
pubmed: 25485714
J Nucl Med. 1998 May;39(5):904-11
pubmed: 9591599
JAMA. 1997 Mar 12;277(10):793-9
pubmed: 9052708
PLoS One. 2013 Nov 06;8(11):e73377
pubmed: 24223109
Arch Neurol. 1991 Nov;48(11):1141-3
pubmed: 1953398
J Alzheimers Dis. 2020;78(2):643-652
pubmed: 33016919
Brain. 2017 Sep 1;140(9):2286-2294
pubmed: 29050382
Alzheimers Res Ther. 2013 Jan 09;5(1):1
pubmed: 23302773
Alzheimers Dement. 2018 Apr;14(4):535-562
pubmed: 29653606
Alzheimers Dement. 2015 Jul;11(7):757-71
pubmed: 26194311
Alzheimers Dement. 2018 Nov;14(11):1470-1481
pubmed: 29499171
Alzheimers Dement (Amst). 2019 Feb 22;11:180-190
pubmed: 30847382
Nature. 1999 Jul 8;400(6740):173-7
pubmed: 10408445
Alzheimers Dement. 2015 Jan;11(1):1-15.e1-4
pubmed: 25443857
Lancet Neurol. 2016 Dec;15(13):1326-1335
pubmed: 27777022
Arch Neurol. 1983 Mar;40(3):143-6
pubmed: 6830452
Psychol Med. 2009 Nov;39(11):1907-11
pubmed: 19335933
N Engl J Med. 2021 May 6;384(18):1691-1704
pubmed: 33720637
Mol Neurodegener. 2008 Nov 20;3:20
pubmed: 19021905
Brain. 2010 Apr;133(Pt 4):1143-54
pubmed: 20375137
Neuropathology. 2015 Aug;35(4):390-400
pubmed: 25964057
Neurology. 2022 Mar 29;98(13):e1315-e1326
pubmed: 35110378
J Neuropathol Exp Neurol. 2012 Apr;71(4):266-73
pubmed: 22437338
Ann Neurol. 2001 Dec;50(6):765-72
pubmed: 11761474
Sci Transl Med. 2011 Apr 6;3(77):77sr1
pubmed: 21471435
Alzheimers Res Ther. 2013 Oct 17;5(5):48
pubmed: 24131566
Neurology. 2010 Jan 19;74(3):201-9
pubmed: 20042704
Neurology. 2014 Jul 15;83(3):253-60
pubmed: 24928124
J Alzheimers Dis. 2011;25(1):3-28
pubmed: 21335653
JAMA Neurol. 2016 Sep 1;73(9):1125-32
pubmed: 27454811
Arch Neurol. 2005 Dec;62(12):1821-30
pubmed: 16344340
J Neurol. 2006 Feb;253(2):139-58
pubmed: 16267640
Biometrics. 1982 Dec;38(4):963-74
pubmed: 7168798
Brain. 2000 Mar;123 Pt 3:484-98
pubmed: 10686172
Nat Med. 1998 Apr;4(4):452-5
pubmed: 9546792
Lancet Neurol. 2022 Feb;21(2):140-152
pubmed: 35065037
J Alzheimers Dis. 2015;50(3):645-58
pubmed: 26757189
Sci Transl Med. 2013 Jun 12;5(189):189ra77
pubmed: 23761040
Alzheimers Dement. 2014 Nov;10(6):869-72
pubmed: 25130656
J Neurosci. 2007 Jun 6;27(23):6174-84
pubmed: 17553989
Alzheimers Dement. 2015 Nov;11(11):1349-57
pubmed: 25916562
Ann Neurol. 2018 Jan;83(1):74-83
pubmed: 29244218
Neuroimage Clin. 2020;28:102491
pubmed: 33395982
Neuroimage Clin. 2018 Apr 25;19:406-416
pubmed: 30035025
Neuroimaging Clin N Am. 2005 Nov;15(4):869-77, xi-xii
pubmed: 16443497
Am J Pathol. 2001 Jun;158(6):2165-75
pubmed: 11395394
J Neuropathol Exp Neurol. 2001 Nov;60(11):1051-61
pubmed: 11706935
Neurology. 1996 Feb;46(2):406-12
pubmed: 8614503
J Alzheimers Dis. 2013;37(4):653-9
pubmed: 23948899
J Alzheimers Dis. 2012;30(4):847-56
pubmed: 22475797
Alzheimers Dement. 2022 Oct;18(10):1754-1764
pubmed: 34854530
J Alzheimers Dis. 2011;26 Suppl 3:321-9
pubmed: 21971471
Ann Neurol. 2015 Sep;78(3):439-53
pubmed: 26040676
Lancet Neurol. 2013 Feb;12(2):129-30
pubmed: 23246540
N Engl J Med. 2012 Aug 30;367(9):795-804
pubmed: 22784036
Alzheimers Res Ther. 2021 Apr 17;13(1):80
pubmed: 33865446
Acta Neuropathol. 2018 Nov;136(5):699-708
pubmed: 30276465
Cereb Cortex. 2004 Jan;14(1):11-22
pubmed: 14654453
Alzheimer Dis Assoc Disord. 2009 Apr-Jun;23(2):91-101
pubmed: 19474567
Alzheimer Dis Assoc Disord. 2006 Oct-Dec;20(4):210-6
pubmed: 17132964
Proc Natl Acad Sci U S A. 2003 May 27;100(11):6382-7
pubmed: 12740439
Alzheimers Dement. 2017 Jan;13(1):8-19
pubmed: 27583651
Clin Chem. 2020 Apr 1;66(4):587-597
pubmed: 32087019
Alzheimers Dement. 2015 Jul;11(7):792-814
pubmed: 26194313
J Neurol. 2017 Mar;264(3):520-528
pubmed: 28054131
Neuroimage. 2004 Oct;23(2):724-38
pubmed: 15488422
Arch Neurol. 2008 Jan;65(1):113-20
pubmed: 18195148
Alzheimers Res Ther. 2019 Apr 22;11(1):34
pubmed: 31010420
Neurobiol Aging. 2015 Dec;36(12):3140-3151
pubmed: 26410308
Clin Investig (Lond). 2012 Oct 1;2(10):975-984
pubmed: 23139856
JAMA. 2014 Dec 17;312(23):2551-61
pubmed: 25514304
Neurology. 1993 Nov;43(11):2412-4
pubmed: 8232972
Ann Neurol. 1988 May;23(5):477-84
pubmed: 3389756
Lancet Neurol. 2018 Mar;17(3):241-250
pubmed: 29397305
Lancet Neurol. 2019 May;18(5):459-480
pubmed: 30879893
Acta Neuropathol. 2009 Jul;118(1):37-52
pubmed: 19306098
Nat Med. 2021 Jul;27(7):1187-1196
pubmed: 34155411
Neuroimage. 2012 Aug 15;62(2):774-81
pubmed: 22248573